Skip to main content

Table 5 Incidence of adverse events with onset 4 weeks after randomization by received treatment

From: Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial

  Enalapril and Metoprolol Placebo Difference between groups
Preferred term No. (%) No. (%) (%) 95% confidence intervals
Total number of patients 21 (100%) 16 (100%)   
Patients with at least one AE 21 (100%) 15 (94%) 6% (−10 to 28%)
Febrile infection 11 (52%) 5 (31%) 21% (−10 to 47%)
Nasopharyngitis 10 (48%) 5 (31%) 16% (−15 to 43%)
Diarrhoea 6 (29%) 1 (6%) 22% (−4 to 44%)
Cough 4 (19%) 5 (31%) −12% (−39 to 15%)
Headache 4 (19%) 5 (31%) −12% (− 39 to 15%)
Mechanical ventilation 3 (14%) 1 (6%) 8% (−16 to 29%)
Abdominal pain upper 3 (14%) 0   14% (−7 to 35%)
Gastroenteritis 3 (14%) 0   14% (−7 to 35%)
Spinal operation 2 (10%) 3 (19%) −9% (−34 to 14%)
Immunisation 2 (10%) 2 (13%) −3% (−27 to 18%)
Pyrexia 2 (10%) 2 (13%) −3% (−27 to 18%)
Lower limb fracture 2 (10%) 1 (6%) 3% (−20 to 23%)
Oropharyngeal pain 2 (10%) 1 (6%) 3% (−20 to 23%)
Chest pain 2 (10%) 0   10% (−11 to 29%)
Fatigue 2 (10%) 0   10% (−11 to 29%)
Humerus fracture 2 (10%) 0   10% (−11 to 29%)
Influenza like illness 2 (10%) 0   10% (−11 to 29%)
Photosensitivity reaction 2 (10%) 0   10% (− 11 to 29%)
Tonsillitis 2 (10%) 0   10% (−11 to 29%)
Upper respiratory tract infection 2 (10%) 0   10% (−11 to 29%)
  1. Data are number of patients, percentage; difference between groups (%), 95% confidence intervals of difference (%)